A Phase 3 Randomized Double-Blind Study of Pembrolizumab versus Placebo in Combination with Adjuvant Chemotherapy with or without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Carcinoma After Surgery with Curative Intent (MK3475 B21/ENGOT-en11/GOG-3053) | NYU Langone Health

Go Back to All Clinical Trials

A Phase 3 Randomized Double-Blind Study of Pembrolizumab versus Placebo in Combination with Adjuvant Chemotherapy with or without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Carcinoma After Surgery with Curative Intent (MK3475 B21/ENGOT-en11/GOG-3053)